

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet		of	
-------	--	----	--

Complete If Known

Application Number	09/280,279
Filing Date	concurrently herewith
First Named Inventor	Jon M. Miller
Group A/I Unit	1616
Examiner Name	Sharareh, S.
Attorney Docket Number	P1109

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	8/18/03
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

(Rev. 7-1-1997) PTO/605

FORM 6-21

6-39

Please type a plus sign (+) inside this box →



Approved for use through 10/31/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Patent and Trademark Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	09/280,279
Filing Date	concurrently herewith
First Named Inventor	Jon M. Miller
Group Art Unit	1616
Examiner Name	Sharareh, S.
Attorney Docket Number	P1109

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Masand PS. <i>J Psychotic Disorders</i> . 1998; 2(3): 4-6
		Bymaster, et al. <i>J. Clin Psychiatry</i> . 1997; 58(suppl 10): 28-36
		Kinon, BJ, Basson B, Szymanski K, et al., <i>Predictors of weight gain during olanzapine treatment</i> . European Neuropsychopharmacology. 1998; 8(suppl. 2):S220.
		Stoa-birketvedt G., et al. <i>Acta Physiol Scan</i> 1997; 16(4): 489-94
		Singh K, Singh PI. <i>Indian J Med Sci</i> 1995; 49 (11): 257-260
		Physician's Desk Reference 52 nd Ed. 1998: pp. 428-34, 1128-31, 1309-13, 1439-41, 1512-16, 1716-18, 1834-38, 1956-59, 2864-67
		Physician's Desk Reference 53 rd Ed. 1999: pp. 3428-32
		Stephen Deutsch, Richard Rosse and Barbara Schwartz; <i>Histamine H₂-Receptor Antagonists in Schizophrenia - Rationale for Use & Therapeutic Potential</i> ; CNN Drugs, pp. 276-284, 10 (4), 1997.
		Robert Leadbetter, et al., <i>Clozapine-Induced Weight Gain: Prevalence and Clinical Relevance</i> , AMJ Psychiatry 149:1 pp. 68-72, January 1992.

Examiner Signature		Date Considered	8/18/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

507

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-95)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1440B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/280,279
Filing Date	concurrently herewith
First Named Inventor	Jon M. Miller
Group Art Unit	1616
Examiner Name	Sharareh, S.
Attorney Docket Number	P1109

Sheet 2 of 2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S		Trino Baptista, et al., Glucose Tolerance and Serum Insulin Levels in an Animal Model of Obesity Induced by Sub-Acute or Chronic Administration of Anti-Psychotic Drugs, Prog. Neuro-Psychopharmacol & Bio. Psychiat. Vol. 23 pp. 277-287, 1999.	
		Drug Facts and Comparisons, pp. 1198 and 2062, 1998 Edition.	
		Donna Wirshing, et al., <i>Novel Anti-Psychotics: Comparison of Weight Gain Liabilities</i> , J Clin Psychiatry,; 60:6, pp. 358-363, June 1999.	
		<i>Letters to the Editor</i> , Am J Psychiatry; 147:12, pp. 1693-1694, December 1990.	
		Jon M. Miller, <i>Reducing Weight Gain Associated with A-typical Anti-Psychotics</i> , Kentucky Psychiatrist, pp. 7-8, 11(1) Winter, 2000.	
		Carl Sherman, <i>H₂-blocker Appears to Cut A-typical Weight Gain</i>, Clinical Psychiatry News pp. 1-2.	
		Ulcer Drug Reduces Weight Gain in Olanzapine Users.	
		David Ginsburg, <i>Nizatidine Treatment of Olanzapine-Induced Weight Gain</i> , Primary Psychiatry, pp. 17-20, 8 (6), 2001.	
		Website Information Medlineplus Drug Information September 21, 2001.	

NO DATE

NO DATE

Examiner Signature	<i>[Signature]</i>	Date Considered	8/18/03
--------------------	--------------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

607